TEPKINLY® ( epcoritamab ) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

4 weeks ago

Company Announcement ...

Ticker	Sentiment	Impact
GMAB	Neutral	16 %
ABBV	Neutral	7 %